BioSpace News Archive

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center for pre-clinical development of investigational tumor-infiltrating lymphocyte therapies.

Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population.

Tetra Bio-Pharma Inc. today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN © 1 and PLENITUDE © ) of QIXLEEF™ for cancer pain.

European Commission Approves KEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma.

Krystal Biotech, Inc. today announced positive topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as VYJUVEKTM, for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB).

Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Monday, December 6, 2021.

Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines.

Kadimastem Ltd. announces a raise of 10 million NIS ($3.2 million) from ILEX Medical (TASE: ILX) one of the largest healthcare companies in Israel, in a private financing round.

Danaher Corporation announced that it will redeem all of the €800,000,000 aggregate principal amount of 2.500% Senior Notes due 2025 issued by DH Europe Finance S.À R.L. and guaranteed by Danaher, at a redemption price equal to the outstanding principal amount and a make-whole premium as specified in the indenture governing the Notes, plus accrued and unpaid interest.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement under which it will acquire Lengo Therapeutics.